$3.55
-0.26-6.7%
Last update: Nov 10, 7:58 PM
Recursion Pharmaceuticals Inc
RXRXNASDAQ
Recursion Pharmaceuticals fell 15.6% from $4.51 to $3.81, behind the S&P 500's +10.0%. Its worst day was Oct 16 (−16.7%), and its low came Mar 30 at $2.84.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Recursion Pharmaceuticals closed at its highest level of the year, 10.0% above where the year started.
+7.6% · S&P 500 +0.5%
EPS of $-0.21 beat the $-0.30 estimate on $35.5M revenue (est. $24.9M).
Story events cover the past 12 months · Times ET
+6.8% · S&P 500 +0.8%
Recursion Pharmaceuticals closed at its lowest level of the year, 37.0% below where the year started.
−3.4% · S&P 500 −0.3%
EPS of $-0.22 beat the $-0.27 estimate on $6.5M revenue (est. $15.9M).
+1.8% · S&P 500 +1.4%
Recursion Pharmaceuticals shares fell 12.8%, while the S&P 500 fell 2.6%.
−12.8% · S&P 500 −2.6%
EPS of $-0.25 missed the $-0.24 estimate on $7.7M revenue (est. $12.9M).
−4.2% · S&P 500 −0.2%
Recursion Pharmaceuticals shares rose 13.3%, while the S&P 500 rose 0.2%.
+13.3% · S&P 500 +0.2%
Recursion Pharmaceuticals shares rose 16.0%, while the S&P 500 rose 0.7%.
+16.0%, the year's best day · S&P 500 +0.7%
Recursion Pharmaceuticals shares fell 16.7%, while the S&P 500 fell 1.1%.
−16.7%, the year's worst day · S&P 500 −1.1%
EPS of $-0.22 beat the $-0.23 estimate on $18.6M revenue (est. $14.0M).
−3.9% · S&P 500 +0.3%
Where it ended: a close of $3.81 on Nov 9, 2026. Up next: Q4 2026 earnings on Feb 24, 2027 (EPS est. $-0.20, revenue est. $7.8M).
Nothing in the past 12 months.
All RXRX dividend historyReplay the year: the line draws itself and stops at each of the 10 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for RXRX and SPY from Benzinga historical bars. Not investment advice.
